Le Lézard
Classified in: Health
Subjects: WOM, FVT

Duchesnay Inc. to Present a Poster on the Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness at 2018 Annual Meeting of the North American Menopause Society (NAMS)


BLAINVILLE, QC, Sept. 12, 2018 /CNW Telbec/ - Duchesnay Inc., a pharmaceutical company specializing in women's health, announced today that it will present a poster on the topic of ospemifene at the 2018 Annual Meeting of the North American Menopause Society (NAMS) in San Diego.

The abstract titled: Efficacy and Safety of Ospemifene in Menopausal Women with Moderate to Severe Vaginal Dryness: A phase 3, Randomized Double-Blind Placebo-Controlled Multicenter Clinical Trial, will be presented as a poster presentation on October 4, 2018, from 6:00 to 7:00 p.m. PST.

This poster will include new data related to the use of ospemifene in menopausal women with moderate to severe vaginal dryness, a symptom of vulvovaginal atrophy (VVA), a part of the genitourinary syndrome of menopause (GSM). Duchesnay is currently seeking approval for this additional indication for ospemifene and this new safety and efficacy data is currently under evaluation by the United States Food and Drug Administration.

"We are excited to share new vaginal dryness data on ospemifene at the upcoming NAMS Annual Meeting to treat this symptom of VVA, as part of the genitourinary syndrome of menopause", affirmed Graziella Soulban, Senior Director of Medical Affairs at Duchesnay. "With an aging population and over 30 years of a woman's life being spent post-menopause, it is increasingly important to promote a broader understanding and access to treatments that may help advance the field of women's health in midlife and beyond."

About Duchesnay
Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women's health. The company focuses on filling the void in terms of scientific research and education and on developing pharmacological solutions that are safe and effective for use during pregnancy and breastfeeding. Duchesnay also commercializes a broad portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at various stages of their lives. For more information, visit www.DuchesnayUSA.com.

 

SOURCE Duchesnay inc.


These press releases may also interest you

at 03:52
The progressive decrease in hearing in elderly people can represent a major problem for their quality of life: it has in fact been demonstrated that critical issues such as these, in addition to being a problem as such, can...

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...



News published on and distributed by: